LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Accueil・Liste d'Actions・AnaptysBio Inc

AnaptysBio Inc

Fermé

SecteurSoins de santé

58.53 -6.7

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

58.18

Max

63.74

Chiffres clés
By Trading Economics
Revenu	35M 50M
Ventes	32M 108M
Marge bénéficiaire	45.833
Employés	104
EBITDA	29M 68M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+28.69% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	441M 2B
Ouverture précédente	65.23
Clôture précédente	58.53

Sentiment de l'Actualité

By Acuity

39%

61%

117 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

19.25 / 21.135 Support & Résistance

AnaptysBio Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 mai 2026, 23:10 UTC

Actions en Tendance

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principaux Mouvements du Marché

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Résultats

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Résultats

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Résultats

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Résultats

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Acquisitions, Fusions, Rachats

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Acquisitions, Fusions, Rachats

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Vinci Buys Canada's Modern Group of Companies

Comparaison

Variation de prix

AnaptysBio Inc prévision

Objectif de Prix

By TipRanks

28.69% hausse

Prévisions sur 12 Mois

Moyen 81.27 USD 28.69%

Haut 140 USD

Bas 50 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

19.25 / 21.135Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

117 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.